Company intelligence / Profile preview

Mediti Pharma Inc.

Montréal, Quebec, Canadapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Mediti Pharma was a Montreal-based private pharmaceutical company focused on developing MP‑101, an mGluR2/3 agonist small molecule originally discovered by Eli Lilly, for the treatment of Alzheimer’s disease–related psychosis. The lead program reached Phase II but was terminated due to statistical futility. No further development has been reported since September 2022.

Therapeutic areas: Psychiatry
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

MP-101

Phase 2

Indications: Alzheimer's disease psychosis

Partnerships

Eli Lilly and Company (originator of compound, risk-sharing arrangement via TVM fund)

Beyond the preview

Go deeper on Mediti Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mediti Pharma Inc..

Explore the full profile